Filing Details

Accession Number:
0001181431-14-032640
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-25 20:34:48
Reporting Period:
2014-09-24
Filing Date:
2014-09-25
Accepted Time:
2014-09-25 20:34:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1369786 Sagent Pharmaceuticals Inc. SGNT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1251512 J Robert Flanagan C/O Sagent Pharmaceuticals, Inc.
1901 North Roselle Road, Suite 700
Schaumburg IL 60195
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-09-24 8,000 $30.30 465,770 No 4 S Indirect See Footnote
Common Stock Disposition 2014-09-25 8,000 $29.72 457,770 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,996 Direct
Common Stock 2,000 Indirect See Footnote
Footnotes
  1. The shares reported are held by Flanagan Family Limited Partnership. Mr. Flanagan is a managing member of E.O. Flanagan LLC, the general partner of Flanagan Family Limited Partnership.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.89 to $30.52, inclusive. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2014.
  3. The shares reported are held of record by CNF Investments II, LLC. Voting and investment decisions with respect to all shares held by CNF Investments II, LLC are exercised by its managing member, Mr. Flanagan. Accordingly, Mr. Flanagan may be deemed the beneficial owner of such shares.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.55 to $30.22, inclusive. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2014.